Lakefront Biotherapeutics vs TG Therapeutics
LKFT and TGTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LKFT and TGTX compare
Lakefront Biotherapeutics grew revenue faster over the last twelve months (304% versus 76.1% for TG Therapeutics).
TG Therapeutics keeps more of each dollar of sales as profit, with a net margin of 55.2% compared with 28.8% at Lakefront Biotherapeutics.
TG Therapeutics scores higher on the StockData Score (9 against 7 for Lakefront Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LKFT | TGTX |
|---|---|---|
| Size and price | ||
| Market cap | – | $9.6B |
| Share price | $34.39 | $62.71 |
| Change, 1 year | 9.9% | 102% |
| Change, 5 years | −29.6% | 162% |
| Beta (5Y) | 0.26 | 0.47 |
| Employees | 452 | 399 |
| StockData Score | ||
| Total score | 7 | 9 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 2 | 4 (better) |
| Health score | 2 | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 22.9× |
| P/S | – | 12.0× |
| P/B | – | 15.9× |
| EV/EBITDA | – | 71.3× |
| P/FCF | – | 552× |
| FCF yield | – | 0.18% |
| Fair value | – | $60.66 |
| Margin of safety | – | −3.4% |
| Growth | ||
| Revenue growth (TTM) | 304% (better) | 76.1% |
| Revenue growth, 5Y average | 18.4% | 427% (better) |
| Net income growth (TTM) | 333% | 630% (better) |
| EPS growth (TTM) | 335% | 641% (better) |
| Profitability | ||
| Gross margin | 97.3% (better) | 82.4% |
| Operating margin | 26.5% (better) | 17.1% |
| Net margin | 28.8% | 55.2% (better) |
| FCF margin | −24.4% | 2.2% (better) |
| Return on equity | – | 100% |
| Return on invested capital | – | 27.8% |
| Financial health | ||
| Debt / equity | – | 1.23 |
| Net debt / EBITDA | – | 0.98 |
| Interest coverage | 285× (better) | 3.6× |
| Current ratio | 20.15 (better) | 4.27 |
| Altman Z-score | – | 6.07 |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | 1.9% |
| Shareholder yield | – | 1.9% |
| Ownership | ||
| Held by institutions | 48.6% | 72.6% |
| Held by insiders | 45.1% | 16.1% |
| Insider net buying, 12 months | – | −$275K |
| Short interest, % of float | – | 22.4% |
Go deeper
- LKFT stock overview
- LKFT income statement
- LKFT valuation and score
- TGTX stock overview
- TGTX income statement
- TGTX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.